These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26804118)

  • 1. KRAS, HRAS and EGFR Mutations in Sporadic Sebaceous Gland Hyperplasia.
    Groesser L; Singer S; Peterhof E; Landthaler M; Heigl U; Schneider-Brachert W; Berneburg M; Hafner C
    Acta Derm Venereol; 2016 Aug; 96(6):737-41. PubMed ID: 26804118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis.
    Georgieva IA; Mauerer A; Groesser L; Herschberger E; Aslanidis C; Dietmaier W; Landthaler M; Hafner C
    Am J Dermatopathol; 2014 Aug; 36(8):635-42. PubMed ID: 23739246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum.
    Shen AS; Peterhof E; Kind P; Rütten A; Zelger B; Landthaler M; Berneburg M; Hafner C; Groesser L
    Hum Pathol; 2015 Feb; 46(2):272-6. PubMed ID: 25532942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent activating HRAS mutations in trichilemmoma.
    Tsai JH; Huang WC; Jhuang JY; Jeng YM; Cheng ML; Chiu HY; Kuo KT; Liau JY
    Br J Dermatol; 2014 Nov; 171(5):1073-7. PubMed ID: 24890286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.
    Kotoula V; Sozopoulos E; Litsiou H; Fanourakis G; Koletsa T; Voutsinas G; Tseleni-Balafouta S; Mitsiades CS; Wellmann A; Mitsiades N
    Endocr Relat Cancer; 2009 Jun; 16(2):565-72. PubMed ID: 19190079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.
    Harms PW; Hovelson DH; Cani AK; Omata K; Haller MJ; Wang ML; Arps D; Patel RM; Fullen DR; Wang M; Siddiqui J; Andea A; Tomlins SA
    Hum Pathol; 2016 May; 51():25-31. PubMed ID: 27067779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF mutations in multiple sebaceous hyperplasias of patients belonging to MYH-associated polyposis pedigrees.
    Ponti G; Venesio T; Losi L; Pellacani G; Bertario L; Sala P; Pedroni M; Petti C; Maffei S; Varesco L; Lerch E; Baggio A; Bassoli S; Longo C; Seidenari S
    J Invest Dermatol; 2007 Jun; 127(6):1387-91. PubMed ID: 17273161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pigmented trichoblastoma developed in a sebaceous nevus: HRAS mutation as a common molecular driver.
    Saraggi D; Salmaso R; Valentini E; Munari G; Vindigni V; Rugge M; Fassan M; Cerroni L
    Pathol Res Pract; 2017 Jul; 213(7):860-862. PubMed ID: 28554764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?
    Vincenten JP; Smit EF; Grünberg K; Postmus PE; Snijders PJ; Witte BI; Heideman DA; Thunnissen E
    Lung Cancer; 2015 Jul; 89(1):19-26. PubMed ID: 25982011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
    Ouerhani S; Elgaaied AB
    Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA, HRAS and KRAS gene mutations in human penile cancer.
    Andersson P; Kolaric A; Windahl T; Kirrander P; Söderkvist P; Karlsson MG
    J Urol; 2008 May; 179(5):2030-4. PubMed ID: 18355852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas.
    Sakamoto H; Shimizu J; Horio Y; Ueda R; Takahashi T; Mitsudomi T; Yatabe Y
    J Pathol; 2007 Jul; 212(3):287-94. PubMed ID: 17534846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
    Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
    Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.
    Groesser L; Herschberger E; Ruetten A; Ruivenkamp C; Lopriore E; Zutt M; Langmann T; Singer S; Klingseisen L; Schneider-Brachert W; Toll A; Real FX; Landthaler M; Hafner C
    Nat Genet; 2012 Jun; 44(7):783-7. PubMed ID: 22683711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consistent mutation status within histologically heterogeneous lung cancer lesions.
    Mattsson JS; Imgenberg-Kreuz J; Edlund K; Botling J; Micke P
    Histopathology; 2012 Oct; 61(4):744-8. PubMed ID: 22458769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.
    Smilek P; Neuwirthova J; Jarkovsky J; Dusek L; Rottenberg J; Kostrica R; Srovnal J; Hajduch M; Drabek J; Klozar J
    Neoplasma; 2012; 59(5):508-15. PubMed ID: 22668015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naevus sebaceus: a mosaic RASopathy.
    Aslam A; Salam A; Griffiths CE; McGrath JA
    Clin Exp Dermatol; 2014 Jan; 39(1):1-6. PubMed ID: 24341474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.